329 related articles for article (PubMed ID: 29189429)
1. New developments in immunotherapy for pediatric solid tumors.
Schultz LM; Majzner R; Davis KL; Mackall C
Curr Opin Pediatr; 2018 Feb; 30(1):30-39. PubMed ID: 29189429
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.
Casey DL; Cheung NV
Cancer Immunol Res; 2020 Feb; 8(2):161-166. PubMed ID: 32015013
[TBL] [Abstract][Full Text] [Related]
3. Adoptive Cell Therapy in Treating Pediatric Solid Tumors.
Tesfaye M; Savoldo B
Curr Oncol Rep; 2018 Aug; 20(9):73. PubMed ID: 30069644
[TBL] [Abstract][Full Text] [Related]
4. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
5. Advances in chimeric antigen receptor immunotherapy for neuroblastoma.
Heczey A; Louis CU
Discov Med; 2013 Dec; 16(90):287-94. PubMed ID: 24333408
[TBL] [Abstract][Full Text] [Related]
6. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
Khalil DN; Smith EL; Brentjens RJ; Wolchok JD
Nat Rev Clin Oncol; 2016 May; 13(5):273-90. PubMed ID: 26977780
[TBL] [Abstract][Full Text] [Related]
7. Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".
Capitini CM; Gottschalk S; Brenner M; Cooper LJ; Handgretinger R; Mackall CL
Pediatr Hematol Oncol; 2011 Sep; 28(6):459-60. PubMed ID: 21854215
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of Childhood Sarcomas.
Roberts SS; Chou AJ; Cheung NK
Front Oncol; 2015; 5():181. PubMed ID: 26301204
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of cancers comes of age.
Yousefi H; Yuan J; Keshavarz-Fathi M; Murphy JF; Rezaei N
Expert Rev Clin Immunol; 2017 Oct; 13(10):1001-1015. PubMed ID: 28795649
[TBL] [Abstract][Full Text] [Related]
10. Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers.
Majzner RG; Heitzeneder S; Mackall CL
Cancer Cell; 2017 Apr; 31(4):476-485. PubMed ID: 28366678
[TBL] [Abstract][Full Text] [Related]
11. GD2-targeted immunotherapy and radioimmunotherapy.
Dobrenkov K; Cheung NK
Semin Oncol; 2014 Oct; 41(5):589-612. PubMed ID: 25440605
[TBL] [Abstract][Full Text] [Related]
12. New developments in immunotherapy for pediatric leukemia.
Foster JB; Maude SL
Curr Opin Pediatr; 2018 Feb; 30(1):25-29. PubMed ID: 29176353
[TBL] [Abstract][Full Text] [Related]
13. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
14. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
Ahmed M; Cheung NK
FEBS Lett; 2014 Jan; 588(2):288-97. PubMed ID: 24295643
[TBL] [Abstract][Full Text] [Related]
15. Disialoganglioside GD2 as a therapeutic target for human diseases.
Suzuki M; Cheung NK
Expert Opin Ther Targets; 2015 Mar; 19(3):349-62. PubMed ID: 25604432
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of immunotherapy for childhood cancers.
Handgretinger R; Schlegel P
Chin Clin Oncol; 2018 Apr; 7(2):14. PubMed ID: 29764159
[TBL] [Abstract][Full Text] [Related]
17. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
Abken H
Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
[TBL] [Abstract][Full Text] [Related]
18. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
Voeller J; Sondel PM
J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
[TBL] [Abstract][Full Text] [Related]
19. Cellular immunotherapy for pediatric solid tumors.
Hegde M; Moll AJ; Byrd TT; Louis CU; Ahmed N
Cytotherapy; 2015 Jan; 17(1):3-17. PubMed ID: 25082406
[TBL] [Abstract][Full Text] [Related]
20. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
